Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

New study identifies DKK3 as a driver of kidney fibrosis

Chronic kidney disease can develop in response to a variety of insults and is characterized by progressive renal fibrosis and atrophy of kidney tubule. Therapeutic options are limited and the disease is often not detected until later stages.

22 Jan 2016

Fibrosis in kidney transplants driven by continuous injury

Clinically, kidney fibrosis can be used to assess stage, progression, and prognosis for both kidney transplants and kidney disease. There is debate as to whether kidney fibrosis is a maladaptive, injury-triggered process that inherently progresses to kidney failure or an adaptive wound-healing process that stabilizes the injury site.

22 Jan 2016

USRDS report shows positive and negative trends in kidney disease in the U.S.

The annual data report from the United States Renal Data System reveals both positive and negative trends in kidney disease in the U.S.

18 Jan 2016

PK molecule could be a target for vascular complications linked to type 1 diabetes

In an article published ahead of print on November 24, 2015 in the journal Diabetes (available at http://dx.doi.org/10.2337/db15-0930), researchers from the Medical University of South Carolina, the American University of Beirut, and Case Western Reserve University report that a molecule called pre-kallikrein (PK) could be a target for the vascular complications associated with type 1 diabetes.

18 Jan 2016

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

From today, people in Scotland with the genetic kidney disease ADPKD could benefit from JINARC® (tolvaptan) following advice issued by the Scottish Medicines Consortium (SMC) for its use in adults with chronic kidney disease (CKD) stages 1-3 at the start of treatment with evidence of rapidly progressing disease.

12 Jan 2016

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers.

5 Jan 2016

Araim Pharmaceuticals forms new strategic collaboration with Vault Bioventures to market novel peptides

Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies.

4 Jan 2016

Infusing small dose of cytokine can prevent or reverse diabetes-related kidney failure

Diabetes is the leading cause of kidney failure, and scientists have found that infusing just a small dose of a cytokine, thought to help cause that failure, can instead prevent or reverse it.

29 Dec 2015

Dynamic light scattering technique may help detect people at risk of cataracts and presbyopia

As we age, proteins in the lenses of our eyes start misbehaving: They unfold and congregate in clusters that block, scatter and distort light as it passes through the lens. A cloudy area, or cataract, forms. In a new study, scientists found that throughout our lifetime, levels of a key protein decline, and may be an early warning sign of a developing cataract.

23 Dec 2015

Prevalence of chronic kidney disease considerably varies across Europe

The first study to carefully characterize the prevalence of chronic kidney disease (CKD) across Europe found considerable variation. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology.

22 Dec 2015

Variant signs worldwide exclusive license and development agreement with L&F Research

Variant Pharmaceuticals, Inc., an emerging pharmaceutical company focusing on rare diseases and other specialty conditions with limited or sub-optimal therapeutic options, announced today a worldwide exclusive license and development agreement with L&F Research LLC to advance development of Variant's lead product, VAR 200.

20 Dec 2015

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

17 Dec 2015

Paying close attention to results of simple blood test can help predict risk of kidney failure, death

Kidney disease in the United States is both common and under-diagnosed, but two new studies led by Johns Hopkins Bloomberg School of Public Health researchers suggest that paying close attention to results of a simple blood test can help predict the likelihood that patients are headed for kidney failure or death.

13 Dec 2015

Rutgers scientists uncover biological pathways that provide insight into tiny cell bubbles

Rutgers scientists have uncovered biological pathways in the roundworm that provide insight into how tiny bubbles released by cells can have beneficial health effects, like promoting tissue repair, or may play a diabolical role and carry disease signals for cancer or neurodegenerative diseases like Alzheimer's.

12 Dec 2015

CRISPR/Cas9 turns hPSCs into cell-based lab model system for polycystic kidney disease

CRISPR/Cas9 is hot. News of the revolutionary gene editing technique that is already shaking up bioscience has finally reached the news media and the public. Now comes a first rate example of how CRISPR is changing the pace of biomedical research by linking up with another cutting edge technology -- human pluripotent stem cells (hPSCs).

12 Dec 2015

EKF biomarker identifies likely development of Diabetic Nephropathy

EKF, announces new data presented in support of soluble Tumour Necrosis Factor Receptor 1 as a biomarker to predict progression of Diabetic Nephropathy.

From EKF Diagnostics 2 Dec 2015

Testosterone treatment can benefit men with Type 2 diabetes

Men with Type 2 diabetes who have low testosterone levels can benefit significantly from testosterone treatment.

30 Nov 2015

IQWiG: Benefit of proteome analysis for detection of diabetic nephropathy remains unclear

The German Institute for Quality and Efficiency in Health Care examined the benefit of a diagnostic-therapeutic strategy using urinary proteome analysis for detection of diabetic nephropathy (DN) versus a conventional diagnostic strategy in patients with diabetes mellitus and arterial hypertension. After publication of the preliminary report in June 2015, interested persons and parties had the opportunity to comment on the preliminary results.

26 Nov 2015

Bile pigment may provide natural protection from heart attacks

New hope in the fight against cardiovascular disease has arrived, following breakthrough research identifying a pigment in our bile which could protect us.